Shares of Cipla
jumped around 2 percent intraday on Tuesday after it announced a commercial
collaboration with UK-based S&D Pharma to enter Czech Republic and
Slovakia. As per the agreement, Cipla will be driving its respiratory product
portfolio in both Czech Republic and Slovakia through a Cipla owned sales force
team, managed by Cipla commercial head. S&D Pharma will physically
distribute all products, including respiratory products, and this portfolio
will increase over the next few years. The company said, in a press statement,
that once regulatory and reimbursement approvals are in place, the Salmeterol-Fluticasone
fixed combination will be launched in both markets underthe name
Fullhale. Apart from Croatia where the combination is already available under
the name Duohal, Cipla recently launched the product in Germany and Sweden. In
Germany the product is distributed under the name ‘Serroflo’, whereas in
Sweden the combination is launched as ‘Salmeterol/Fluticasone Cipla’.
0 comments:
Post a Comment